Major clinical research advances in gynecologic cancer in 2021

J Gynecol Oncol. 2022 Mar;33(2):e43. doi: 10.3802/jgo.2022.33.e43.


In the 2021 series, we not only summarized the major clinical research advances in gynecologic oncology but also added discussions to every part, based on communications at the conference. A review of cervical cancer included adjuvant treatments such as radiation and chemoradiation (concurrent or sequential) after radical hysterectomy in early cervical cancer, and immune checkpoint inhibitors in advanced, recurrent, and metastatic disease. Ovarian cancer research included studies of secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer, and various trials of immune checkpoint inhibitors with or without vascular endothelial growth factor inhibitors and conventional chemotherapy. The rechallenge of poly (ADP-ribose) polymerase inhibitor maintenance in heavily pretreated ovarian cancer were also addressed. For uterine corpus cancer, dostarlimab (anti-programmed cell death protein 1 antibody) alone, or a tyrosine kinase inhibitor in combination with pembrolizumab for advanced, metastatic, or recurrent endometrial cancer were reviewed. The survival differences between the intensive and minimalist follow-up protocols were also described. In this review, we compared salpingectomy with delayed oophorectomy and salpingo-oophorectomy in terms of quality of life in BRCA 1 and 2 pathogenic variant carriers.

Keywords: Adjuvant Chemotherapy; Adjuvant Radiotherapy; Cytoreduction Surgical Procedures; Immunotherapy; Molecular Targeted Therapy; Poly(ADP-Ribose) Polymerase; Prevention.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents* / therapeutic use
  • Carcinoma, Ovarian Epithelial / drug therapy
  • Female
  • Genital Neoplasms, Female* / drug therapy
  • Humans
  • Immune Checkpoint Inhibitors
  • Neoplasm Recurrence, Local / drug therapy
  • Ovarian Neoplasms* / drug therapy
  • Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
  • Quality of Life
  • Uterine Cervical Neoplasms* / surgery
  • Vascular Endothelial Growth Factor A / therapeutic use


  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Immune Checkpoint Inhibitors
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Vascular Endothelial Growth Factor A
  • dostarlimab